Medicus Pharma (TSX-V:MDCX) Ltd has announced the appointment of Huma Qamar as its chief scientific officer and head of R&D program.
The biotech company said Qamar has robust experience in developing Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, billing and compliance audits, and medical affairs team management, having most recently served as the head of clinical development & clinical operations at Ocugen Inc.
"Huma is a trusted and a respected leader in the industry, well-liked by her peers and superiors, and is well known for her laser sharp focus and sense of urgency to deliver measurable results in drug development," Medicus Pharma CEO Dr Raza Bokhari said in a statement.
As well, the company announced the election of James Quinlan as board chair of Skinject Inc, Medicus Pharma’s wholly owned subsidiary, as well as Carolyn Bonner and Edward Brennan as Skinject board members.
Medicus Pharma is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through US Food and Drug Administration (FDA) approved clinical trials.
Contact Sean at sean@proactiveinvestors.com